Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 9Genitourinary 5CNS 3Breast 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Breast Neoplasms 2Acrocephalosyndactylia 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × infigratinib × Breast × Clear all
NCT04504331 2026-02-12

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Stanford University

Phase 1 Terminated
4 enrolled 11 charts
Breast

Breast Neoplasms

NCT01928459 2020-12-09

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Novartis

Phase 1 Completed
62 enrolled
Breast

Acrocephalosyndactylia, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡